Hillstream BioPharma has selected immune-oncology clinical research organization, OncoBay Clinical, to provide comprehensive clinical and regulatory support for the clinical development program for its lead drug candidate HSB-1216. HSB-1216, Hillstream’s most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death of drug-resistant cancers. As part of the agreement, OncoBay Clinical’s engagement will provide comprehensive clinical expertise across data management, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, and observational studies. Additionally, OncoBay will leverage the support of a multitude of top scientific advisors and highly experienced teams to support Hillstream.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HILS:
- Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
- Hillstream BioPharma announces pharmacokinetic data of HSB-1216
- Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
- Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023
- Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023